India
oi – Ankur Singh
New Delhi, 28 January. There has been an increase in the cases of corona infection in the country for some time, but the pharmaceutical company Cipla has claimed that now the demand for corona medicines like Remdesivi, Tocilizumab, Fabipiravir is no longer the same and its demand is declining. I have come The company says that when the Delta variant wreaked havoc in the second wave of Corona, the demand for these drugs had increased significantly at that time, but now there is a decline in its demand.
Kedar Upadhyay, Global CFO of Cipla said that now the need of hospitalization of corona patients is decreasing. Not only this, the fever is also not getting very high. Now paracetamol is being needed more all over the world. The impact of the third wave will be less on the people, so Cipla is focusing on making sure that the medicines are available to the people. The wave of corona in many cities is almost over now but people are still weak. The demand for vitamins may increase in the coming days.
The third wave of corona was mainly caused by Omicron, which infects more people than the earlier variant, but its effect is much less than the earlier variant. Omicron is making people suffer from mild fever, body ache, sore throat. Paracetamol and multivitamin medicines are more effective for these problems. Micro Lab’s Dolo, GSK’s Crocin, and Calpol are in high demand in the market.
Also read- COVID: Gujarat recovers from third wave, 23197 cured against 12911 new patients
Talking about Indian companies, Cipla is producing a lot of medicines for the treatment of Kovid. These include antivirals, monoclonal antibodies, corticosteroids, vitamins, sanitizers, masks, rapid antigen test kits, etc. Explain that Cipla did a lot of business in India in FY21 and the company’s profit increased by 15 percent. Although the sales information related to Kovid has not been given by the company, but on behalf of the company it has been said that the investment of the company has increased by Rs.19160 crore.
-
Passes in COVID-19 antiviral pill trial, reduces risk of death and hospitalization by 50% -
World Rhino Day: Why did Assam decide to burn 2,500 rhino horns, that too on this special occasion? Learn
-
Glenmark claimed after the study that Fabiflu drug is effective in the treatment of corona
-
Cipla requested the central government, permission should be given to increase the price of asthma and respiratory medicines
-
US Army is testing ‘infallible medicine’, army soldiers will not get old by eating ‘miraculous’ medicine
-
SC asks for original video of statement from Baba Ramdev, alleging insult to doctors
-
DRDO’s 2-DG drug is doing wonders in the treatment of corona, shocking results in new study
-
Now preparing to deliver vaccine and medicine by drone in the country, this state is at the forefront
-
Has Israel found Corona’s ‘magic medicine’, know the truth of the viral claim
-
Baba Ramdev’s troubles are not decreasing, IMA filed a complaint in Delhi
-
What is Antibody Cocktail Therapy, which started the treatment of corona in the country? Know everything about it
-
Center has made fun of vaccination drive, government’s management has completely failed: Sisodia
English summary
Demand of covid related drugs decreased now says drug company Cipla.
Story first published: Friday, January 28, 2022, 11:30 [IST]
hindi.oneindia.com
